Abbott Receives FDA Approval for Minimally Invasive Portico™ with FlexNav™ TAVR System to Treat Patients with Aortic Valve Disease

Share this story

– Transcatheter aortic valve replacement (TAVR) procedure treats people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery

– With Portico approval, Abbott offers the industry’s most comprehensive portfolio of structural heart solutions in the U.S.

Leave a Comment

Your email address will not be published. Required fields are marked *